Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -52.23% is 50% above its 5-year average of -104.09%, near the high end of its 5-year range (-184.49%–-27.04%).
10.32% above its 12-month average of -58.24%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.39%.
RETURN ON ASSETS (ROA)
-52.23%
RETURN ON ASSETS (ROA) AVG TTM
-58.24%
RETURN ON ASSETS (ROA) AVG 3Y
-82.00%
RETURN ON ASSETS (ROA) AVG 5Y
-104.09%
RETURN ON ASSETS (ROA) AVG 10Y
-173.54%
RETURN ON ASSETS (ROA) AVG 15Y
-93.18%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.32%
CURRENT VS 3Y AVG
+36.31%
CURRENT VS 5Y AVG
+49.82%
CURRENT VS 10Y AVG
+69.90%
CURRENT VS 15Y AVG
+43.95%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
-66.50%
vs the sector median at left
Satellos Bioscience Inc.
Market Cap
$10.44M
Return on Assets (ROA)
-52.23%
TTM Avg
-58.24%
3Y Avg
-82.00%
5Y Avg
-104.09%
Market Cap
$10.51M
Return on Assets (ROA)
N/A
TTM Avg
-37.02%
3Y Avg
-41.41%
5Y Avg
-41.74%
Market Cap
$10.33M
Return on Assets (ROA)
-149.72%
TTM Avg
-86.94%
3Y Avg
-66.39%
5Y Avg
-60.64%
Market Cap
$10.55M
Return on Assets (ROA)
-88.09%
TTM Avg
-90.94%
3Y Avg
-60.82%
5Y Avg
-50.49%
Market Cap
$10.32M
Return on Assets (ROA)
N/A
TTM Avg
-21.71%
3Y Avg
-73.35%
5Y Avg
-116.85%
Market Cap
$10.65M
Return on Assets (ROA)
-132.59%
TTM Avg
-75.28%
3Y Avg
-65.73%
5Y Avg
-52.31%
Market Cap
$10.05M
Return on Assets (ROA)
-204.84%
TTM Avg
-224.84%
3Y Avg
-332.29%
5Y Avg
-789.37%
Market Cap
$10.94M
Return on Assets (ROA)
-185.94%
TTM Avg
-166.39%
3Y Avg
-133.67%
5Y Avg
-110.62%
Market Cap
$10.96M
Return on Assets (ROA)
-404.58%
TTM Avg
-269.82%
3Y Avg
-269.82%
5Y Avg
-269.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.44M | -52.23% | -58.24% | -82.00% | -104.09% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A | -37.02% | -41.41% | -41.74% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.33M | -149.72% | -86.94% | -66.39% | -60.64% |
| Lifeward Ltd. (LFWD)vs › | $10.55M | -88.09% | -90.94% | -60.82% | -50.49% |
| Polyrizon Ltd. (PLRZ)vs › | $10.32M | N/A | -21.71% | -73.35% | -116.85% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | -132.59% | -75.28% | -65.73% | -52.31% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.05M | -204.84% | -224.84% | -332.29% | -789.37% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -185.94% | -166.39% | -133.67% | -110.62% |
| Caring Brands, Inc. (CABR)vs › | $10.96M | -404.58% | -269.82% | -269.82% | -269.82% |
| MetaVia Inc. (MTVA)vs › | $9.88M | -108.85% | -94.23% | -71.21% | -107.74% |
ROA
-52.2%
ROE
-57.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -78.00% |
| 2024-12-31 | -38.48% |
| 2023-12-31 | -27.04% |
| 2022-12-31 | -184.49% |
| 2021-12-31 | -157.08% |
| 2020-12-31 | -139.45% |
| 2019-12-31 | -132.01% |
| 2018-12-31 | -955.58% |
| 2017-12-31 | -89.95% |
| 2016-12-31 | -60.76% |
| 2015-12-31 | -46.07% |
| 2014-12-31 | -28.37% |
| 2013-12-31 | -144.27% |
| 2012-12-31 | -120.88% |
| 2011-12-31 | -35.03% |
| 2010-12-31 | -115.87% |
| 2009-12-31 | -49.88% |
| 2008-12-31 | -187.09% |
| 2007-12-31 | -158.20% |
